Prodia the CRO Receives Frost & Sullivan 2026 Customer Value Recognition
SAN ANTONIO — September 8, 2026 PT Prodia Diacro Laboratories (Prodia the CRO) has received Frost & Sullivan’s 2026...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN ANTONIO — September 8, 2026 PT Prodia Diacro Laboratories (Prodia the CRO) has received Frost & Sullivan’s 2026...
RESEARCH TRIANGLE PARK, N.C., March 2, 2026 IQVIA Holdings Inc. (NYSE: IQV) announced that Chairman and Chief Executive Officer...
